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CC BY-NC-ND license (http://creativeBackground/purpose: Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma
type. The immunophenotypic and genetic features of DLBCL in Taiwan have not been charac-
terized.
Methods: In this study, we performed immunohistochemical analysis and interphase fluores-
cence in situ hybridization (FISH) using tissue microarray sections to investigate a cohort of
unselected DLBCL cases in a single institution in Taiwan from 1990 to 2010.
Results: Of the 153 cases investigated, CD10, bcl-6, and MUM1 were expressed in 16.3%, 71.2%,
and 71.9% cases, respectively, with 27.5% (n Z 42) of cases being classified as having a
germinal center B-cell (GCB) origin by the Hans algorithm. By FISH analysis, 19.6%, 4.6%,
26.1%, and 3.9% cases showed rearrangement at IGH, BCL2, BCL6, and MYC loci, respectively,
including three (2.0%) cases of double-hit lymphoma. As compared with the non-GCB tumors,
GCB tumors more frequently expressed CD10 (p < 0.001) and bcl-6 (p Z 0.001) with less
frequent expression of MUM1 (p Z 0.007). Moreover, GCB tumors more frequently exhibitedave no conflicts of interest relevant to this article.
t of Pathology, Chi-Mei Medical Centre, 901, Chung-Hwa Road, Yong-Kang District, Tainan 71004,
imei.org.tw (S.-S. Chuang).
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an Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the
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962 S.-T. Chang et al.Table 1 Source of antibodies fo
Antibody Clone Diluti
CD3 Poly 1:300
CD5 4C7 1:100
CD10 56C6 1:100
CD20 L26 1:300
bcl-2 124 1:300
bcl-6 PG-B6P 1:120
MUM1 MUM1P 1:100
a Antigen retrieval solution: Epito
Biosystems Newcastle Ltd).
b Source: DakoCytomation, Glostr
Tyne, U.K.rearrangement at the BCL2 (p Z 0.024) and MYC (p Z 0.038) loci than non-GCB tumors.
However, there was no survival difference between these two groups.
Conclusion: In this first series of DLBCL evaluation from Taiwan, we found that the relative fre-
quency of GCB tumors among DLBCL was low in most East Asian countries. There is a wide
range of BCL2 rearrangement rates, higher in the West and lower in East Asia. A larger and/
or national study is warranted to better understand the immunophenotypic and molecular fea-
tures of DLBCL in Taiwan and their respective impact on patient survival.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous
group of aggressive B-cell lymphomas and is the most com-
mon lymphoma type worldwide, including in Taiwan, ac-
counting for 30e40% of the cases.1,2 DLBCL is heterogeneous
with a wide variation in morphology, immunophenotype,
genetic features, and patient outcomes. Using complemen-
tary DNA microarrays, DLBCLs could be divided into prog-
nostically important subgroups and patients with germinal
center B cell (GCB)-like tumors had a significantly better
overall survival than those with non-GCB type.3,4 At present,
it is impractical to perform gene expression profiling on all
newly diagnosed cases of DLBCL. Immunohistochemistry
may serve as a surrogate to divide DLBCL cases into GCB and
non-GCB subtypes and provide similar prognostic informa-
tion as complementary DNA microarray does.5 Several
immunohistochemical algorithms have been proposed
including Hans et al,5 Muris et al,6 Choi et al,7 and Meyer
et al8 (Tally) algorithms. Hans algorithm5 has been shown to
have good correlation with results of the corresponding gene
expression profiling; in addition, the three antibodies (CD10,
bcl-6, and MUM1) used are readily available for the great
majority of diagnostic pathology laboratories. Hence, it is
the most widely used algorithm for classifying cell of origin
(COO) of DLBCL cases into GCB versus non-GCB subtypes.
Most prior studies on the prognostic impact of COO
focused on DLBCL cases recruited from clinical trials, indi-
cating that these patients might have better performance
status, which might reflect that their disease might be less
aggressive.9,10 Some other studies focused on the immuno-
phenotypic and genetic alterations of DLBCL of specificr immunohistochemistry and st
on Antigen retrievala
Bond ERS 2
Bond ERS 1
Bond ERS 2
Bond ERS 1
Bond ERS 2
0 Bond ERS 2
Bond ERS 1
pe Retrieval Solution 1 (ERS 1),
up, Denmark; Epitomics, Burlingaorgans, such as DLBCL primarily in the stomach, intestine,
central nervous system, and breast.11e15 In this study, we
investigated the immunohistochemical features and the
common lymphoma-associated chromosomal translocations
in a cohort of nonselective DLBCL cases from Taiwan.
Methods
Samples
Consecutive cases of DLBCL from 1990 to 2010 at Chi-Mei
Hospital (Tainan, Taiwan) were used for construction of
tissue microarray array (TMA) as previously described.12
Cases of DLBCL were selected when the paraffin blocks
contain adequate tissue for TMA, irrespective of clinical
presentation or pathological features. The diagnostic
criteria of DLBCL were based on the 2008 World Health
Organization (WHO) classification of tumors of hematopoi-
etic and lymphoid tissues.16 The Chi-Mei Medical Centre
Institutional Review Board approved the study.
Immunohistochemistry
Biopsy/surgical specimens were fixed in 10% formalin,
processed by routine methods, and embedded in paraffin.
Sections of 4-mm thickness from TMA blocks or from whole-
tissue blocks were used with the labeled streptavi-
dinebiotineperoxidase method (Super Sensitive Link-Label
HRP Detection Systems, BioGenex Laboratories, San
Ramon, CA, USA) and an antigen-retrieval technique was
applied as needed for each antibody. Table 1 lists theaining conditions.
Antibody incubation (min) Antibody sourceb
30 DakoCytomation
20 Leica Biosystems Newcastle
40 Leica Biosystems Newcastle
20 DakoCytomation
20 DakoCytomation
40 Leica Biosystems Newcastle
20 DakoCytomation
pH 6.0 and Epitope Retrieval Solution 2 (ERS 2), pH 9.0 (Leica
me, CA, USA; Leica Biosystems Newcastle Ltd., Newcastle upon
Phenotype and FISH of DLBCL in Taiwan 963antibodies used and the staining conditions in this study.
Appropriate positive controls were used in all stains. For
immunohistochemical studies with CD10, bcl-6, and MUM1,
positive signals  30% of neoplastic cells were considered
positive. For the few cases with unsatisfactory staining
results such as the artifact resulting in inadequate tissues in
the TMA sections, whole-tissue block sections of the cases
were used for immunohistochemical study. The stained
sections were interpreted by two experienced hema-
topathologists (S.-T.C. and S.-S.C.) blinded to other stains
or follow-up data. Those cases with initial discordant
interpretation were double scoped to reach a consensus.
Classification of COO was based on Hans algorithm.5 Ac-
cording to this scheme, DLBCL tumor cells expressing CD10,
regardless of bcl-6 or MUM1 status, were considered to be
of GCB origin. Those with a CD10/bcl-6þ/MUM1 pheno-
type were also considered to be of GCB origin, whereas
those with CD10/bcl-6 or CD10/bcl-6þ/MUM1þ pheno-
type were considered to be of non-GCB origin.
Fluorescence in situ hybridization
Locus-specific interphase fluorescence in situ hybridization
(FISH) was performed on TMA tissue sections. In brief,
deparaffinized sections were pretreated by pressure cooking
for 3 minutes in EDTA buffer (1mM, pH 8.0) and subsequent
incubation in pepsin solution for 25 minutes at 37C to in-
crease DNA accessibility. Sections were then dehydrated
through ethanol and air dried. The appropriate probe mix
(1.0 mL) was applied to the tissue section and covered with a
round 10-mm cover slip. Both probe and target DNA were
simultaneously denatured at 80C for 25 minutes and incu-
bated for up to 2 days at 45C. Posthybridization washes
were performed according to the “rapid-wash protocol”
provided by Vysis (Downers Grove, IL, USA). Sections were
counterstained with 40,6-diamidino-2-phenylindole and
mounted in VECTASHIELD antifade solution (Vector Labora-
tories, Burlingame, CA, USA). Image acquisition and pro-
cessing were performed as previously described.12 FourTable 2 Clinicopathological features of DLBCL patients in this
Total (n Z 153) G
Median age (range), y 66 (17e94) 6
Male/Female (ratio) 83/70 (1.19) 2
Nodal/extranodal (nodal %)a 66/84 (44.0%) 1
Morphology (C/I/A) ratio 109/35/9 (12.1:3.9:1) 3
Stages III or IV (%) 25.9 2
CD10 expression (%) 16.3 5
Bcl-6 expression (%) 71.2 9
MUM1 expression (%) 71.9 3
IGH rearrangement (%) 19.6 2
BCL2 rearrangement (%) 4.6 1
BCL6 rearrangement (%) 26.1 1
MYC rearrangement (%) 3.9 9
Bold values indicate statistically significant values.
* Statistical analyses between the GCB and non-GCB groups by Pearso
A Z anaplastic morphology; C Z centroblastic morphology; DLBCL Z
I Z immunoblastic morphology.
a The organ of tumor origin was indeterminate in three cases with th
(56%) of extranodal origin.dual-color break-apart rearrangement probes directed at
IGH, BCL2, BCL6, and MYC loci (Dako Japan, Tokyo, Japan)
were used for all cases.
Statistical analysis
We presented the data as frequency counts with percent-
ages for categorical variables. Age was reported as median
with range, and data on male/female and morphology types
were reported as ratios. For comparing the difference be-
tween GCB and non-GCB groups, Pearson’s Chi-square test
or Fisher’s exact test was used. KaplaneMeier plot was used
to describe the survival probability and log-rank test was
used to compare the difference between the two groups.
STATA (version 12; Stata Corp., College Station, TX, USA)
was used to perform all statistical analyses. Significance
was set at p < 0.05 (2-tailed).
Results
Patient characteristics
Table 2 summarizes the patient characteristics. The median
age of the 153 patients (83 males and 70 females) was
66 years (range, 17e94 years), with a male-to-female ratio
of 1.19. Two tumors were relapsed, four were DLBCL
transformed from mucosa-associated lymphoid tissue lym-
phoma (3 from gastric and 1 from thyroid), three were
uncertain in clinical history, whereas the remaining 144
(94.1%) cases were de novo. The organ of tumor origin was
indeterminate in three cases as there was extensive nodal
and extranodal involvement. Of the remaining 150 cases, 66
(44%) were of nodal origin, whereas 84 (56%) were of
extranodal origin.
Pathological and immunohistochemical findings
Morphological subtype and immunohistochemical results are
listed in Table 2 and representative pictures in Figure 1.study.
CB* (n Z 42) Non-GCB* (n Z 111) p*
7 (26e89) 66 (17e94)
1/21 (1.0) 62/49 (1.27) 0.516
9/23 (45.2%) 47/61 (43.5%) 0.113
4/6/2 (17.0:3.0:1) 75/29/7 (10.7:4.1:1) 0.265
9.7 25.0 0.749
9.5 0 <0.001
7.6 38.7 0.001
5.7 85.6 0.007
1.4 18.9 0.776
1.9 1.8 0.024
9.0 28.8 0.338
.5 1.8 0.038
n’s Chi-square test or Fisher’s exact test.
diffuse large B-cell lymphoma; GCB Z germinal center B cell;
e remaining 150 cases divided into 66 (44%) of nodal origin and 84
Figure 1 (A) Scanning power of tissue microarray (hematoxylin and eosin stain). (B) Oil immersion view of one core showing a
centroblastic subtype of diffuse large B-cell lymphoma comprising large atypical lymphocytes among some reactive small lymphoid
cells. Representative immunohistochemical images showing positive reaction to (C) CD10, (D) bcl-6, and (E) MUM1.
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accounting for 71.2% (109/153) of cases, followed by
immunoblastic (22.9%) and anaplastic (5.9%) morphologies.
There was no statistical significance in morphology between
GCB and non-GCB tumors. CD10, bcl-6, and MUM1 were
expressed in 16.3% (25/153 cases), 71.2% (109), and 71.9%
(110) of cases, respectively (Figure 1). According to the Hans
algorithm incorporating CD10, bcl-6, and MUM1, 27.5%
(nZ 42) of cases were classified as having a GCB origin and
72.5% (n Z 111) of cases as having a non-GCB origin. Inter-
estingly, the proportion of GCB phenotype in nodal and
extranodal presentation was similar: 28.8% (19/66) of cases
in nodal and 27.4% (23/84) of cases in extranodal tumors.Figure 2 A representative case of double-hit lymphoma with du
IGH, (B) BCL2, and (C) MYC foci but not at BCL6.The three indeterminate (nodal vs. extranodal) cases were
all of non-GCB phenotype. As compared with the non-GCB
group, the GCB tumors more frequently expressed CD10
(p < 0.001) and bcl-6 (p Z 0.001), and less frequently
expressed MUM1 (p Z 0.007; Pearson’s Chi-square test or
Fisher’s exact test).
FISH findings
FISH results are listed in Table 2. A total of 30 (19.6%) cases,
seven (4.6%) cases, 40 (26.1%) cases, and six (3.9%) cases
were positive for IGH, BCL2, BCL6, and MYC rearrange-
ments, respectively (Figure 2). GCB tumors more frequentlyal-color break-apart probes showing rearrangements at the (A)
Table 3 Clinicopathological features of three double-hit lymphoma cases.
Case No. Age (y) Sex Location Stage Tx CD10 Bcl-6 MUM1 Phenotype IGH BCL2 BCL6 MYC FU (mo)
325 75 F LN, neck I CVP x6 Positive Positive Negative GCB R R NR R NED (173)
417 74 F LN, neck III Unknown Positive Positive Positive Non-GCB R NR R R DOD (9)
712 36 M LN, neck III R-CHOP x6 Negative Negative Positive Non-GCB R NR R R NED (104)
CVP Z cyclophosphamide, vincristine, and prednisolone; DOD Z died of disease; FU Z follow-up; GCB Z germinal center B cell;
LNZ lymph node; NEDZ no evidence of disease; NRZ not rearranged; RZ rearranged; R-CHOPZ rituximab plus cyclophosphamide,
doxorubicin, vincristine, and prednisolone; Tx Z treatment.
Phenotype and FISH of DLBCL in Taiwan 965carried rearrangement in the BCL2 (p Z 0.024) and MYC
(pZ 0.038) loci than non-GCB tumors (Pearson’s Chi-square
test or Fisher’s exact test). There was no statistical dif-
ference in BCL6 rearrangement (pZ 0.338) between these
two groups. Three (2.0%) cases were double-hit lymphomas
including two with rearrangement involving MYC and BCL6
and one involving MYC and BCL2. Their clinicopathological
features are listed in Table 3. All three were nodal lesions.
One patient died of disease in 9 months, whereas the
remaining two were long-term survivors after excisional
biopsy and chemotherapy.
Patient outcome
Staging results were unavailable in 16 patients. Of the
remaining 137 patients, 43.1% (59 patients) were at Stage I,
31.3% (n Z 43) at Stage II, 14.6% (n Z 20) at Stage III, and
10.9% (n Z 15) at Stage IV. The treatment modalities were
heterogeneous, ranging from supportive care only, oral
chemotherapy, to systemic chemotherapy with or without
radiotherapy. Seventeen patients were lost to follow-up;
the survival rates of the remaining 136 patients at 1 year,
2 years, and 5 years were 62.6%, 49.2%, and 41.6%,
respectively. Figure 3 shows KaplaneMeier estimates of
overall survival. There was no statistical difference in
overall survival between patients with GCB and those with
non-GCB tumors (p Z 0.9362, log-rank test). The median
survival of patients with GCB tumors was 25 months (95%
confidence interval, 12e42 months), and that for patientsFigure 3 KaplaneMeier plot shows no statistical difference
in overall survival between patients with germinal center B-cell
(GCB) and non-GCB tumors. CI Z confidence interval.with non-GCB tumors was 30 months (95% confidence in-
terval, 16e58 months).Discussion
There are many studies analyzing various differentiation
antigens and COO, and their prognostic significance in pa-
tients with DLBCL. Table 4 summarizes prior studies on GCB
versus non-GCB origin of DLBCL reported from various
countries based on Hans algorithm.5,8e10,17e19 The propor-
tion of GCB phenotype in nonselective DLBCL cases is
around 50% in Japan and Western countries. However, in
East Asian countries other than Japan, the rates were 30.6%
(52/170 cases) in Korea and 33% (21/63) in China.17,19 Both
figures are slightly higher, but not much different from our
figure at 27.5% (42/153). It seems that there might be
geographic difference in the proportion of GCB phenotype
among DLBCL cases. In the past 10 years, we routinely
stained each newly diagnosed DLBCL case in our institution
using whole-block tissue section for GCB versus non-GCB
phenotype. We analyzed consecutive DLBCL cases from
2010 to 2015 and found that GCB phenotype accounted for
28.4% (61/211 cases), a figure very close to the 27.5% re-
ported in this study using TMA sections for cases from 1990
to 2010. This finding indicated that the relatively low fre-
quency of GCB phenotype in Taiwan is a genuine finding,
and not due to technical issues related to TMA. In this study
including consecutive nodal and extranodal tumors, a low
expression rate of CD10 (16.6%) and a high expression rate
of MUM1 (72.2%) led to a low frequency of GCB phenotype
(27.5%) among the DLBCL cases.Table 4 Frequency of DLBCL with GCB phenotype (based
on the Hans algorithm) in various geographic regions.
Country/region
[total case no. (n)]
GCB%
(Case No.)
Reference
International (431)a 56.1 (242) Visco et al10
Western (169) 46.7 (79) Meyer et al8
Spain (149) 40.9 (61) Gutierrez-Garcia et al9
Japan (730) 48.2 (352) Seki et al18
Korea (170) 30.6 (52) Yoon et al19
China (63) 33 (21) Li et al17
Taiwan (153) 27.5 (42) This study
DLBCL Z diffuse large B-cell lymphoma; GCB Z germinal
center B cell.
a International, International DLBCL Rituximab-CHOP Con-
sortium Program Study.
Table 5 Chromosomal translocations of DLBCL by fluorescence in situ hybridization in different geographic regions.
Country (n) BCL2 BCL6 MYC Reference
Spain (219) 15.1 (26/172) 27.9 (46/165) 6.8 (12/176) Valera et al22
Denmark (193) 24.6 (47/191) d 11.1 (21/189) Green et al27
Italy (71) 17 (12/71) 15 (11/71) 6 (4/71) Vitolo et al26
Netherland (156) 16.0 (25/156) 31.0 (36/116) 6.6 (10/151) Kramer et al24
USA (563) 18.2 (80/440) 32.2 (121/376) 9.0 (39/433)a Tzankov et al25
Japan (61) 11 (7/61) 13 (8/61) 10 (6/61) Kawamoto et al23
Korea (186) 3.4 (5/145) 17.5 (24/137) 9 (9/41) Yoon et al19
China (63) 22 (11/50) 34 (11/32) 30 (8/27) Li et al17
Taiwan (153) 4.6 (7/153) 26.1 (40/153) 3.9 (6/153) This study
Data are presented as % (n/N ).
DLBCL Z diffuse large B-cell lymphoma.
a Two fluorescence in situ hybridization probes for MYC alteration were applied including a locus-specific identifier IGH/MYC/CE 8 tri-
color, dual-fusion probe, and the locus-specific MYC dual-color, break-apart probe (both from Abbott/Vysis, Downers Grove, IL, USA).
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neoplasms, BCL6 translocation is the most common abnor-
mality in DLBCL, accounting for up to 30% of cases.20
Translocation of BCL2 occurs in 20e30% of cases, whereas
MYC rearrangement was observed in up to 10% of cases.20
MYC rearrangement may coexist with IGH-BCL2 trans-
location in a DLBCL, so-called double-hit lymphoma; less
commonly, BCL6 gene is rearranged instead of BCL2 in a
double-hit lymphoma.21
Table 5 summarizes a few prior representative studies on
chromosomal translocations of DLBCL by interphase
FISH.17,19,22e26 In most studies, the most common trans-
location occurred at the BCL6 locus, accounting for 20e30%
cases including our figure of 26.1%. However, there are some
outliers such as those from Italy, Japan, and Korea, all at
around 15%.19,23,26,27 The relative frequency of BCL2 rear-
rangement varied significantly in different countries, ranging
from as low as 3.4% in Korea to the highest at 24.6% in
Denmark. MYC rearrangement rate was at around 5e10% in
most studies, with only an unusual high figure at 30% from
China.17 The translocation rate of BCL6 in this current study
(26.1%) was in line with the data reported in the WHO classi-
fication (up to 30%), whereas that ofMYC translocation in this
study was lower (3.9% vs. up to 10%).20 Our BCL2 rearrange-
ment rate is lower than the 20e30% rate as described in the
WHO classification, yet it is similar to other East Asian coun-
tries, indicating a possible underlying ethnic difference.
Gene expression profiling studies initially enabled DLBCL
to be divided into GCB and activated B-cell (ABC)-like sub-
types, which define high- and low-risk patient groups when
treated with chemotherapy. Attempts to reproduce the
prognostic classification immunohistochemically have, how-
ever, provided inconsistent results.3,4 The addition of ritux-
imab to conventional anthracycline-based chemotherapy has
improved clinical outcomes forpatientswithDLBCL. Fuet al28
reported that addition of rituximab to standard CHOP
(cyclophosphamide, doxorubicin, vincristine, and predniso-
lone) chemotherapy improves the survival of both the GCB-
like and non-GCB-like subtypes of DLBCL and the subclassifi-
cation of DLBCL on the basis of the COO continues to have
prognostic importance in the rituximab era.28 Seki et al18
reported that in their DLBCL patients treated with CHOP,
the GCB subtype was associated with better overall survival,
whereas the non-GCB subtype was associated with worseoverall survival.18 However, in their rituximab plus CHOP
group, the patients with non-GCB subtype showed improved
survival and the prognostic impact of COO was no longer
present. Similarly, Koh et al29 also found that in the rituximab
area, there was no impact of COO on the survival of DLBCL
patients. Nymanet al30 usedamodifiedalgorithmwithMUM1/
IRF4 and FOXP1positivities as ABC-likemarkers andwere able
to distinguish the DLBCL patients between the ABC-like and
other DLBCL subtypes with a significantly worse outcome in
the former group. By contrast, when the classification of the
same cohort was performed according to the Hans algorithm
(GCB vs. non-GCB), no significant difference in survival was
observed. Results of improved survival with rituximab addi-
tion indicate that the relevance of previously recognized
prognostic factors might be abolished and should be re-
evaluated. In our study, the major focus was to establish
the baseline data of immunophenotype (COO by Hans algo-
rithm) and genetic alterations of DLBCL in Taiwan, as these
have never been investigated systemically. There was no
survival difference between GCB and non-GCB groups in our
study. However, due to the nature of this study, it is probably
inappropriate to emphasize the survival impact of COO as the
patients were treated heterogeneously including some criti-
cally ill patientswithout chemotherapy orwith only palliative
chemotherapy.
This retrospective study has some limitations, most
importantly, the study cases span a long period of time
dating back to year 1990 and the clinical information was
incomplete in some patients. Nonetheless, we were able
to use TMA to obtain satisfactory immunohistochemical
and FISH results and characterize the frequency of the
expression of various differential antigens and common
lymphoma-associated chromosomal translocations.
Further prospective multicenter or large-scale studies
entailing homogeneous treatment regimens are warranted
to better understand the immunophenotypic and molecu-
lar features of DLBCL in Taiwan and their respective
prognostic impact.Acknowledgments
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